Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Turn Therapeutics Inc ( (TTRX) ) has shared an update.
On October 27, 2025, Turn Therapeutics, Inc. entered into a Global Supply, Development, and License Agreement with Medline Industries, LP. This collaboration aims to develop, manufacture, and commercialize health products leveraging Turn’s PermaFusion® platform, with Medline handling global distribution across over 100 countries. The agreement outlines a multi-year framework for co-development and manufacturing scale-up, with an initial term of three years and automatic renewals, potentially enhancing Turn’s market reach and operational capabilities.
More about Turn Therapeutics Inc
Turn Therapeutics, Inc. operates in the healthcare industry, focusing on the development and commercialization of professional and consumer health products using its proprietary PermaFusion® delivery platform.
Average Trading Volume: 1,706,336
For a thorough assessment of TTRX stock, go to TipRanks’ Stock Analysis page.